Chemical formula: C₂₀H₁₈ClF₂N₅O₃ Molecular mass: 449.84 g/mol PubChem compound: 72165228
Asciminib is indicated for:
Population group: only adults (18 years old or older)
Asciminib is indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase (Ph+ CML-CP) previously treated with two or more tyrosine kinase inhibitors.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Asciminib is contraindicated in the following cases:
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
